TG Therapeutics, Inc. (TGTX)

Oncology Corporate Profile

Stock Performance

11.1000
-0.6500

HQ Location

3 Columbus Circle, 15th Floor
New York, NY 10019

Company Description

TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycol-engineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor, jointly with Rhizen Pharmaceuticals S A.  The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B?lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. TG Therapeutics is headquartered in New York City.

Website: http://www.tgtherapeutics.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ublituximab / TG-1101 (+ ibrutinib)anti-CD20 monoclonal antibody (humanized)Chronic Lymphocytic Leukemia (CLL)II
ublituximab / TG-1101 (+ ibrutinib)anti-CD20 monoclonal antibody (humanized)Mantle Cell Lymphoma (MCL)II
TG-1101anti-CD20 monoclonal antibodyAcute Myelogenous Leukemia (AML)I
TGR 1201 (+ TG 1101 + pembrolizumab)Chronic Lymphocytic Leukemia (CLL)I
TGR-1202PI3K inhibitorChronic Lymphocytic Leukemia (CLL)I
TGR-1202PI3K inhibitorNon-Hodgkin's Lymphoma (NHL)I
TGR-1202PI3K inhibitorVarious cancer typesI
IRAK4kinase inhibitorChronic Lymphocytic Leukemia (CLL)Preclinical
IRAK4kinase inhibitorNon-Hodgkin's Lymphoma (NHL)Preclinical
IRAK4kinase inhibitorWaldenstrom macroglobulinemia (WM)Preclinical

View additional information on product candidates here »

Pipeline image

Source


http://www.tgtherapeutics.com/

Recent News Headlines

TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2017 American Association for Cancer Research (AACR) Annual Meeting

3/20/2017 11:03 am

[GlobeNewswire] - NEW YORK, March 20, 2017-- TG Therapeutics, Inc., today announced that preclinical data for the Company’ s anti-PD-L1 monoclonal antibody, has been selected for presentation at the upcoming American Association ...

TG Therapeutics, Inc. to Present at the 27th Annual Oppenheimer Healthcare Conference

3/17/2017 11:03 am

[GlobeNewswire] - NEW YORK, March 17, 2017-- TG Therapeutics, Inc. today announced that Michael S. Weiss, the Company’ s Executive Chairman and Chief Executive Officer, will present at the 27 th Annual Oppenheimer Healthcare ...

TG Therapeutics and ImmunoGen are Models of Institutional Investor Attention

3/16/2017 01:03 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 16, 2017 / One question many investors have is how much emphasis should be put on insider trading reports and institutional investor activity. The recent activity of TG ...

TG Therapeutics, Inc. to Present at the 29th Annual ROTH Conference

3/13/2017 11:03 am

[GlobeNewswire] - NEW YORK, March 13, 2017-- TG Therapeutics, Inc. today announced that Michael S. Weiss, the Company’ s Executive Chairman and Chief Executive Officer, will present at the 29 th Annual ROTH Conference, ...

TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2016 Financial Results and Business Update

3/10/2017 12:03 pm

[GlobeNewswire] - Company solidifies balance sheet with approximately $89 M in gross proceeds through the combination of $57.5 M public offering and $31 M from at-the-market sales facility completed prior to the offering. ...

TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2016 Financial Results and Business Update

3/9/2017 09:03 pm

[GlobeNewswire] - NEW YORK, March 09, 2017-- TG Therapeutics, Inc., today announced that a conference call will be held tomorrow, Friday, March 10, 2017 at 8:30am ET to discuss results for the fourth quarter and year-end ...

TG Therapeutics, Inc. Announces Pricing of $50 Million Public Offering of Common Stock

3/9/2017 02:01 pm

[GlobeNewswire] - NEW YORK, March 09, 2017-- TG Therapeutics, Inc. today announced the pricing of an underwritten public offering of 5,128,206 shares of its common stock at a price of $9.75 per share, with expected gross ...

TG Therapeutics Announces Proposed Public Offering of Common Stock

3/8/2017 09:00 pm

[GlobeNewswire] - NEW YORK, March 08, 2017-- TG Therapeutics, a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases, ...

DEADLINE TODAY FOR TGTX INVESTORS: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

3/7/2017 03:02 pm

[Accesswire] - IRVINE, CA / ACCESSWIRE / March 7, 2017 / Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against TG Therapeutics, Inc. ("TG Therapeutics" or the "Company") ...

DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against TG Therapeutics, Inc. and Announces a Lead Plaintiff Deadline of March 7, 2017 - TGTX

3/7/2017 03:00 pm

[PR Newswire] - NEW YORK, March 7, 2017 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of TG Therapeutics, Inc. ...